The UAE has authorised the usage of gene substitute remedy for a brand new age group of sufferers dwelling with spinal muscular atrophy (SMA), strengthening the nation’s place as a regional chief in entry to superior medical innovation.
The Emirates Drug Institution (EDE) introduced the regulatory approval of Itvisma (onasemnogene abeparvovec), a one-time gene remedy for eligible adults and kids aged two years and above. With the choice, the UAE turns into the second nation globally to authorise the therapy for this expanded affected person group.
Itvisma addresses the foundation genetic reason behind SMA by changing the faulty gene chargeable for the situation. The remedy has been proven to enhance motor operate and cut back reliance on long-term supportive therapies.
UAE approves expanded SMA gene therapy
The approval varieties a part of EDE’s broader technique to speed up affected person entry to high-value and breakthrough medicines, consistent with the UAE’s ambition to construct a world-class, revolutionary and sustainable healthcare system.
Dr. Fatima Al Kaabi, Director-Basic of the Emirates Drug Institution, mentioned the choice displays the UAE’s dedication to sufferers with uncommon genetic ailments. “Granting the regulatory approval for Itvisma is a big step demonstrating the UAE’s dedication to offering sufferers with the most recent superior genetic therapies, significantly these with uncommon genetic ailments like spinal muscular atrophy,” she mentioned.
She added that the approval highlights the effectivity of the nationwide well being system in evaluating revolutionary therapies in line with the best scientific requirements inside efficient timeframes. “We’re dedicated to making sure sufferers obtain speedy entry to cutting-edge therapy choices that enhance their high quality of life,” Al Kaabi mentioned.
In line with EDE, the remedy was authorised primarily based on scientific proof displaying clear and sustained enhancements in sufferers’ motor skills, alongside a constantly constructive security profile all through scientific analysis.
Al Kaabi famous that the choice reinforces worldwide confidence within the UAE’s regulatory mannequin, which balances pace, scientific rigour and transparency to make sure well timed and dependable entry to innovation. She added that EDE will proceed supporting medical innovation that enhances high quality of life and advances the nation’s healthcare ecosystem.
Mohamed Ezz Eldin, Head of the GCC Cluster at Novartis, mentioned the authorisation represents a significant step for sufferers and households affected by SMA. He emphasised that collaboration with EDE goals to make sure quick and equitable entry to the remedy for individuals who had been beforehand unable to learn from a one-time gene therapy.
Ezz Eldin added that the UAE’s assist for revolutionary medicines can assist alter the illness trajectory for SMA sufferers, noting that the approval displays Novartis’s continued dedication to neurological and neuromuscular problems.
EDE mentioned the milestone helps its mission to place the UAE as a regional hub for pharmaceutical innovation, delivering superior genetic therapies that meet the best requirements of security and high quality.
